JP6833193B2 - 色素幹細胞の分化抑制剤、白髪予防剤、及び白髪評価方法 - Google Patents
色素幹細胞の分化抑制剤、白髪予防剤、及び白髪評価方法 Download PDFInfo
- Publication number
- JP6833193B2 JP6833193B2 JP2016161060A JP2016161060A JP6833193B2 JP 6833193 B2 JP6833193 B2 JP 6833193B2 JP 2016161060 A JP2016161060 A JP 2016161060A JP 2016161060 A JP2016161060 A JP 2016161060A JP 6833193 B2 JP6833193 B2 JP 6833193B2
- Authority
- JP
- Japan
- Prior art keywords
- hair
- cxcl12
- expression level
- stem cells
- gray hair
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000004209 hair Anatomy 0.000 title claims description 166
- 210000000130 stem cell Anatomy 0.000 title claims description 56
- 239000000049 pigment Substances 0.000 title claims description 44
- 239000003795 chemical substances by application Substances 0.000 title claims description 29
- 230000003449 preventive effect Effects 0.000 title claims description 8
- 239000003112 inhibitor Substances 0.000 title claims description 6
- 230000024245 cell differentiation Effects 0.000 title description 12
- 238000011156 evaluation Methods 0.000 title description 6
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 claims description 98
- 230000014509 gene expression Effects 0.000 claims description 97
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 claims description 96
- 238000000034 method Methods 0.000 claims description 70
- 238000012360 testing method Methods 0.000 claims description 44
- 108090000623 proteins and genes Proteins 0.000 claims description 31
- 239000000126 substance Substances 0.000 claims description 28
- 230000004069 differentiation Effects 0.000 claims description 26
- 239000000203 mixture Substances 0.000 claims description 16
- 102000004169 proteins and genes Human genes 0.000 claims description 16
- 108020004999 messenger RNA Proteins 0.000 claims description 14
- 238000012258 culturing Methods 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 8
- 238000012216 screening Methods 0.000 claims description 8
- 239000000654 additive Substances 0.000 claims description 5
- 230000000996 additive effect Effects 0.000 claims description 3
- 230000001900 immune effect Effects 0.000 claims description 2
- 150000001413 amino acids Chemical group 0.000 description 24
- 210000003780 hair follicle Anatomy 0.000 description 19
- 210000002752 melanocyte Anatomy 0.000 description 19
- 101150067717 CXCL12 gene Proteins 0.000 description 14
- 239000000523 sample Substances 0.000 description 13
- 241000282414 Homo sapiens Species 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 8
- 108020004459 Small interfering RNA Proteins 0.000 description 8
- 102000003425 Tyrosinase Human genes 0.000 description 8
- 108060008724 Tyrosinase Proteins 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 108010051081 dopachrome isomerase Proteins 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 6
- 238000003753 real-time PCR Methods 0.000 description 6
- 108020004463 18S ribosomal RNA Proteins 0.000 description 5
- 108010050345 Microphthalmia-Associated Transcription Factor Proteins 0.000 description 5
- 102000013760 Microphthalmia-Associated Transcription Factor Human genes 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- -1 jojoba oil Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 238000010807 real-time PCR kit Methods 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 210000004761 scalp Anatomy 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 108010012236 Chemokines Proteins 0.000 description 3
- 102000019034 Chemokines Human genes 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000013068 control sample Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 101000942967 Homo sapiens Leukemia inhibitory factor Proteins 0.000 description 2
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 239000012124 Opti-MEM Substances 0.000 description 2
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000008099 melanin synthesis Effects 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 210000000603 stem cell niche Anatomy 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- LGQKSQQRKHFMLI-SJYYZXOBSA-N (2s,3r,4s,5r)-2-[(3r,4r,5r,6r)-4,5,6-trihydroxyoxan-3-yl]oxyoxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)CO[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)OC1 LGQKSQQRKHFMLI-SJYYZXOBSA-N 0.000 description 1
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 1
- LGQKSQQRKHFMLI-UHFFFAOYSA-N 4-O-beta-D-xylopyranosyl-beta-D-xylopyranose Natural products OC1C(O)C(O)COC1OC1C(O)C(O)C(O)OC1 LGQKSQQRKHFMLI-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 102100022716 Atypical chemokine receptor 3 Human genes 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 235000015001 Cucumis melo var inodorus Nutrition 0.000 description 1
- 240000002495 Cucumis melo var. inodorus Species 0.000 description 1
- 108010036941 Cyclosporins Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- SQNRKWHRVIAKLP-UHFFFAOYSA-N D-xylobiose Natural products O=CC(O)C(O)C(CO)OC1OCC(O)C(O)C1O SQNRKWHRVIAKLP-UHFFFAOYSA-N 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000678890 Homo sapiens Atypical chemokine receptor 3 Proteins 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 239000012098 Lipofectamine RNAiMAX Substances 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- GWFGDXZQZYMSMJ-UHFFFAOYSA-N Octadecansaeure-heptadecylester Natural products CCCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCCCC GWFGDXZQZYMSMJ-UHFFFAOYSA-N 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical class CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229960001777 castor oil Drugs 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 210000005064 dopaminergic neuron Anatomy 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 235000008524 evening primrose extract Nutrition 0.000 description 1
- 239000010475 evening primrose oil Substances 0.000 description 1
- 229940089020 evening primrose oil Drugs 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 239000008266 hair spray Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- DWMMZQMXUWUJME-UHFFFAOYSA-N hexadecyl octanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCCC DWMMZQMXUWUJME-UHFFFAOYSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000003866 melanoblast Anatomy 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Natural products OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- NKBWPOSQERPBFI-UHFFFAOYSA-N octadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCCCC NKBWPOSQERPBFI-UHFFFAOYSA-N 0.000 description 1
- IIGMITQLXAGZTL-UHFFFAOYSA-N octyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCC IIGMITQLXAGZTL-UHFFFAOYSA-N 0.000 description 1
- 229940073665 octyldodecyl myristate Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000003498 protein array Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 229940079889 pyrrolidonecarboxylic acid Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 230000021148 sequestering of metal ion Effects 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 230000023895 stem cell maintenance Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
[1]CXCL12(stromal cell-derived factor−1)を有効成分として含有することを特徴とする、毛包内バルジ領域の色素幹細胞の分化抑制剤。
[2]CXCL12(stromal cell-derived factor−1)を有効成分として含有することを特徴とする、白髪の予防及び/又は改善剤。
[3]前記CXCL12が、以下の(a)〜(c)のいずれかのタンパク質又はその部分ペプチドである、[1]又は[2]に記載の剤。
(a) 配列番号2に示すアミノ酸配列からなるタンパク質
(b) 配列番号2に示すアミノ酸配列において、1若しくは数個のアミノ酸が欠失、置換若しくは付加されたアミノ酸配列からなり、かつ毛包内バルジ領域の色素幹細胞の分化抑制活性を有するタンパク質
(c) 配列番号2に示すアミノ酸配列と80%以上の配列同一性を有するアミノ酸配列からなり、かつ毛包内バルジ領域の色素幹細胞の分化抑制活性を有するタンパク質
[4]被験対象より採取した毛髪の毛根部におけるCXCL12の発現量を指標として、毛髪の白髪化を評価する方法。
[5]被験対象に抗白髪剤を使用し、使用する前と後の該被験対象より採取した毛髪の毛根部におけるCXCL12の発現量を指標として、毛髪に対する抗白髪剤の有効性を評価する方法。
[6]以下の工程を含む、白髪の予防及び/又は改善物質のスクリーニング方法。
(1)被験物質を毛髪の毛根部と接触させて培養する工程
(2)上記毛根部におけるCXCL12の発現量を測定する工程
(3)被験物質を接触させない毛根部におけるCXCL12の発現量を測定する工程
(4)上記工程(2)で測定した発現量が、上記工程(3)で測定した発現量より増加した被験物質を白髪の予防及び/又は改善物質として選択する工程
[7]前記CXCL12の発現量が、前記毛根部から抽出したmRNAを試料とし、PCR法によって測定される、[4]〜[6]のいずれかに記載の方法。
[8]前記CXCL12の発現量が、前記毛根部から抽出したタンパク質を試料とし、免疫学的方法によって測定される、[4]〜[6]のいずれかに記載の方法。
本発明の色素幹細胞の分化抑制剤は、CXCL12を有効成分として含有し、色素幹細胞のニッチ(幹細胞の生態的適所)である毛包内バルジ領域の色素幹細胞の分化を抑制できる。
本発明の毛髪の白髪化を評価する方法は、被験対象より採取した毛髪の毛根部における
CXCL12の発現量を指標として用いる。具体的には、被験対象の特定部位の毛髪より採取した毛根部を用意し、該毛根部におけるCXCL12の発現量を測定し、該発現量に基づいて毛髪の白髪化を評価する。本発明において「白髪化の評価」とは、白髪の発生の予測、白髪になる素因の有無の判定、白髪の程度(本数や範囲)の判定、白髪化の進行度の判定などをいう。
CXCL12は、白髪の予防及び/又は改善物質のスクリーニング方法にも使用できる。本発明のスクリーニング方法によれば、CXCL12の発現の亢進を指標として、白髪の予防及び/又は改善物質を精度よく、かつ迅速、正確にスクーニングできる。本発明のスクリーニング方法は、具体的には以下の工程を含む。
(1)被験物質を毛髪の毛根部と接触させて培養する工程
(2)上記毛根部におけるCXCL12の発現量を測定する工程
(3)被験物質を接触させない毛根部におけるCXCL12の発現量を測定する工程
(4)上記工程(2)で測定した発現量が、上記工程(3)で測定した発現量より増加した被験物質を白髪の予防及び/又は改善物質として選択する工程
ヒトの頭髪(黒髪)を毛抜きで採取し、PBS(-)にて2回洗浄した後、毛根部をメスで毛球、バルジ下、バルジ、バルジ上の4区画に分割した。Trizol Reagent(Invitrogen社製)によって各区画の細胞からRNAを抽出した。2-STEPリアルタイムPCRキット(Applied Biosystems社製)を用いて、抽出したRNAをcDNAに逆転写した後、ABI7300(Applied Biosystems社製)により、下記のプライマーセットを用いてリアルタイムPCR(95℃:15秒間、60℃:30秒間、40cycles)を実施し、CXCL12の発現を確認した。その他の操作は定められた方法に従って実施した。
5'-CATGCCGATTCTTCGAAAGC-3' (配列番号3)
5'-CGAGTGGGTCTAGCGGAAAG-3' (配列番号4)
18srRNA(内部標準)用プライマーセット:
5'-CCGAGCCGCCTGGATAC-3' (配列番号5)
5'-CAGTTCCGAAAACCAACAAAATAGA-3'(配列番号6)
ヒトの黒髪と白髪をそれぞれ毛抜きで採取し、PBS(-)にて2回洗浄した後、Trizol Reagent(Invitrogen社製)によって毛根部の細胞からRNAを抽出した。2-STEPリアルタイムPCRキット(Applied Biosystems社製)を用いて、抽出したRNAをcDNAに逆転写した後、ABI7300(Applied Biosystems社製)により、前記のCXCL12用プライマーセットを用いてリアルタイムPCR(95℃:15秒間、60℃:30秒間、40cycles)を実施し、CXCL12の発現を確認した。その他の操作は定められた方法に従って実施した。
色素幹細胞モデルとしては、初期継代(継代数1〜4)のヒト正常メラノサイト(NHEM)を用いることができるため(Nishimura EK, Suzuki M, Igras V, Du J, Lonning S, Miyachi Y, Roes J, Beermann F, Fisher DE, Key roles for transforming growth factor beta in melanocyte stem cell maintenance. Cell Stem Cell. 2010 Feb 5;6(2):130-40.)、継代数2のNHEMを用いた。Medium254(Thermo Fisher Scientific社製)に1%となるようにhuman melanocyte growth supplement(Thermo Fisher Scientific社製)を添加した培地(Medium254+)にて培養したNHEM(東洋紡社製)を、24ウェルプレートに4x104個ずつ播種し、24時間培養した。10 ng/mLとなるようにCXCL12を添加した新しいMedium254+に培地を交換し、さらに72時間培養した後、NHEMからRNAを抽出した。2-STEPリアルタイムPCRキット(Applied Biosystems社製)を用いて、抽出したRNAをcDNAに逆転写した後、ABI7300(Applied Biosystems社製)により、下記のプライマーセットを用いてリアルタイムPCR(95℃:15秒間、60℃:30秒間、40cycles)を実施し、メラノサイト分化関連遺伝子(MITF、DCT、TYR)の発現を確認した。その他の操作は定められた方法に従って実施した。
5'-CGGGAAACTTGATTGATCT-3'(配列番号7)
5'-CTCTGTGGGAAAAATACACG-3' (配列番号8)
DCT用プライマーセット:
5'-GGAATGCTTTGGAAGGGTTTG-3' (配列番号9)
5'-AAAGCGTTTGTCCCGTTCAG-3' (配列番号10)
TYR用プライマーセット:
5'-TGCGGTGGGAACAAGAAATC-3'(配列番号11)
5'-GAAGAATGATGCTGGGCTGAGT-3'(配列番号12)
ヒトの頭髪(黒髪)を毛抜きで採取し、外科用メスにてバルジ部位を採取し、0.25%トリプシン-EDTA中で30分間処理した。遠心操作によって得られた毛包幹細胞(hair follicle stem cell; HFSC)をHumedia-KG2(クラボウ社製)を用いて培養した。一定量まで増殖したHFSCを、0.25%トリプシン-EDTAを用いてシャーレから剥離し、遠心後、Humedia-KG2に懸濁して24ウェルプレートに5x104個ずつ播種した。24時間後、500 μLのOpti-MEM(Thermo Fisher Scientific社製)にCXCL12に対するsiRNA (siCXCL12:下記のsiRNA-1、siRNA-2、siRNA-3を混合して使用)又はネガティブコントロールのsiRNA(siNC, Bioneer社製)を50 nMとなるように添加し、さらにLipofectamine RNAiMAX(Thermo Fisher Scientific社製)を2 μL添加して懸濁し、20分後にHumedia-KG2と交換することでsiRNAをトランスフェクションした。
センス:GAUUCUUCGAAAGCCAUGU (配列番号13)
アンチセンス:ACAUGGCUUUCGAAGAAUC (配列番号14)
<siRNA-2>
センス:CCAGAGCCAACGUCAAGCA (配列番号15)
アンチセンス:UGCUUGACGUUGGCUCUGG (配列番号16)
<siRNA-3>
センス:CAACAGACAAGUGUGCAUU (配列番号17)
アンチセンス:AAUGCACACUUGUCGGUUG (配列番号18)
Claims (8)
- CXCL12(stromal cell-derived factor−1)を有効成分として含有することを特徴とする、毛包内バルジ領域の色素幹細胞の異所性分化抑制剤。
- 請求項1に記載の色素幹細胞の異所性分化抑制剤を含有することを特徴とする、白髪の予防及び/又は改善のための毛髪用組成物。
- CXCL12(stromal cell-derived factor−1)を含有することを特徴とする、色素幹細胞培養用の培地添加剤。
- 被験対象より採取した毛髪の毛根部におけるCXCL12の発現量を指標として、毛髪の白髪化を評価する方法。
- 被験対象に抗白髪剤を使用し、使用する前と後の該被験対象より採取した毛髪の毛根部におけるCXCL12の発現量を指標として、毛髪に対する抗白髪剤の有効性を評価する方法。
- 以下の工程を含む、白髪の予防及び/又は改善物質のスクリーニング方法。
(1)被験物質を毛髪の毛根部と接触させて培養する工程
(2)上記毛根部におけるCXCL12の発現量を測定する工程
(3)被験物質を接触させない毛根部におけるCXCL12の発現量を測定する工程
(4)上記工程(2)で測定した発現量が、上記工程(3)で測定した発現量より増加した被験物質を白髪の予防及び/又は改善物質として選択する工程 - 前記CXCL12の発現量が、前記毛根部から抽出したmRNAを試料とし、PCR法によって測定される、請求項4〜6のいずれか1項に記載の方法。
- 前記CXCL12の発現量が、前記毛根部から抽出したタンパク質を試料とし、免疫学的方法によって測定される、請求項4〜6のいずれか1項に記載の方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016161060A JP6833193B2 (ja) | 2016-08-19 | 2016-08-19 | 色素幹細胞の分化抑制剤、白髪予防剤、及び白髪評価方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016161060A JP6833193B2 (ja) | 2016-08-19 | 2016-08-19 | 色素幹細胞の分化抑制剤、白髪予防剤、及び白髪評価方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018027920A JP2018027920A (ja) | 2018-02-22 |
JP6833193B2 true JP6833193B2 (ja) | 2021-02-24 |
Family
ID=61248133
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016161060A Active JP6833193B2 (ja) | 2016-08-19 | 2016-08-19 | 色素幹細胞の分化抑制剤、白髪予防剤、及び白髪評価方法 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6833193B2 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7100351B2 (ja) * | 2018-06-05 | 2022-07-13 | 日本メナード化粧品株式会社 | Cxcl12発現促進剤 |
KR102117504B1 (ko) * | 2018-07-23 | 2020-06-01 | 아주대학교산학협력단 | Sdf1 프로모터 영역을 이용한 피부 미백제 스크리닝 방법 |
-
2016
- 2016-08-19 JP JP2016161060A patent/JP6833193B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP2018027920A (ja) | 2018-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Mastrogiannaki et al. | β-Catenin stabilization in skin fibroblasts causes fibrotic lesions by preventing adipocyte differentiation of the reticular dermis | |
JP6249777B2 (ja) | 皮膚におけるダイニンの調節 | |
JP6584494B2 (ja) | メラニン産生細胞のhmgb1活性化を阻害する方法、そのような阻害に好適な薬剤を特定する方法 | |
JP5027528B2 (ja) | 皮膚老化の検査方法 | |
US8632827B2 (en) | Modulation of thymosin beta-4 in skin | |
JP2015028036A (ja) | Loxタンパク質とnrageタンパク質との通常の共発現と相互作用を復元させる物質 | |
KR20060123256A (ko) | 모발의 태모화 방법 및 조성물 | |
JP6833193B2 (ja) | 色素幹細胞の分化抑制剤、白髪予防剤、及び白髪評価方法 | |
JP2017536803A (ja) | 皮膚の老化の防止および/または緩和、および/または皮膚の保湿、および/または皮膚色素沈着の抑制のためのセストリン(sestrin)アクチベーター | |
EP2783212B1 (en) | Novel markers of papillary and reticular fibroblasts and uses thereof | |
JP5886278B2 (ja) | 皮膚の加齢を防止および/もしくは減弱し、並びに/または皮膚に潤いを与えるのに用いるためのマイクロrna阻害剤 | |
JP5933443B2 (ja) | Pdgf−bb活性亢進による皮膚賦活化 | |
CN115227774A (zh) | 大白蝴蝶兰萃取物用于制备抑制糖化终产物生成的组合物的用途 | |
KR101032271B1 (ko) | 피부세포 재생용 조성물, 그 제조 방법, 피부세포 재생 방법 및 화장료 조성물 | |
JP7015518B2 (ja) | 毛包幹細胞の未分化状態維持剤 | |
CN102498221A (zh) | 基于aff-4表达筛选抗白发剂的方法 | |
JP5852854B2 (ja) | メラノサイト分化誘導抑制剤及びその使用方法 | |
US20160326492A1 (en) | Reconstituted nipple skin model | |
US20230167498A1 (en) | Method of determining the phenotype of a hair follicle | |
WO2023210403A1 (ja) | 毛球部毛根鞘(dsc)細胞の毛髪再生能を評価する方法、毛髪を再生するための組成物及びその製造方法 | |
JP2006223144A (ja) | プロスタグランジンfシンターゼ及び/又はカルボニルリダクターゼ−1を指標とした育毛剤のスクリーニング方法 | |
JP6678231B2 (ja) | 皮膚バリア機能を改善するため、ならびに/または皮膚の老化を予防および/もしくは軽減するため、ならびに/または皮膚を保湿するのに使用するためのuc.291の活性化因子 | |
JP2016210746A (ja) | 血管内皮細胞増殖因子の産生促進剤 | |
WO2014093053A1 (en) | Modulation of thymosin beta-4 in skin | |
Class et al. | Patent application title: INHIBITORS OF MICRO-RNAS FOR USE FOR PREVENTING AND/OR ATTENUATING SKIN AGEING AND/OR FOR HYDRATING SKIN Inventors: Eleonora Candi (Rome, IT) Gennaro Melino (Rome, IT) Gaelle Saintigny (Paris, FR) Gaelle Saintigny (Paris, FR) Christian Mahe (Neuilly Sur Seine, FR) Assignees: CHANEL PARFUMS BEAUTE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190611 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200616 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200806 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210105 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210120 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6833193 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |